Compare YELP & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | URGN |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2011 | 2016 |
| Metric | YELP | URGN |
|---|---|---|
| Price | $22.81 | $29.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $29.17 | ★ $29.29 |
| AVG Volume (30 Days) | ★ 1.3M | 615.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.15 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,464,955,000.00 | $1,128,000.00 |
| Revenue This Year | $2.19 | $129.09 |
| Revenue Next Year | $2.34 | $70.96 |
| P/E Ratio | $80.93 | ★ N/A |
| Revenue Growth | ★ 3.75 | N/A |
| 52 Week Low | $19.60 | $11.51 |
| 52 Week High | $35.99 | $32.37 |
| Indicator | YELP | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 62.40 |
| Support Level | $21.22 | $26.67 |
| Resistance Level | $24.69 | $30.34 |
| Average True Range (ATR) | 1.04 | 1.50 |
| MACD | 0.20 | -0.14 |
| Stochastic Oscillator | 38.80 | 86.75 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.